Jul 2026· Research journal of biotechnology· 0 citations
TL;DR
The latest functional genomics strategies used to examine NCRNAS are discussed and their transformative ability in accurate therapy is highlighted, highlighting their transformative ability in accurate therapy.
Abstract
Noncoding RNA (NCRNA), once considered genomic
"dark matter," has emerged as an essential regulator of
gene expression and is rapidly implicated in the
pathogenesis of various human diseases. Functional
genomics has brought a revolution to our
understanding of these RNA molecules, including
microRNAs, long noncoding RNAs and circular RNAs
(circRNAs), by enabling their expression, interaction
and large-scale analysis of the regulatory network.
With the advancement of high-throughput sequencing,
CRISPR-based gene editing and transcription,
functional genomics offers a wealth of insights into how
ncRNAs contribute to the onset, progression and tissue
specificity of diseases. These approaches facilitate the
identification of NCRNA biomarkers, highlight their
epigenetic and transcriptional control mechanisms and
illustrate their interactions with DNA, RNA and
proteins. In cancer, heart, neurodegenerative and
autoimmune diseases, converted NCRNA profiles are
now recognized as a significant reorganization of
signaling pathways and cellular homeostasis.
Additionally, a functional genomics background
improves transcriptional noise, enhancing AIDS,
clinical accuracy and medical goal discovery in
separating disease-specific NCRNAs. The integration
of computational biology, machine learning and
systems biology further enhances our ability to
interpret NCRNA tasks and predict their roles in the
disease network. Despite significant progress,
challenges remain in functionally validating NCRNAs
and translating genomic data into clinical
applications. This study discusses the latest functional
genomics strategies used to examine NCRNAS and
highlights their transformative ability in accurate
therapy.
These findings call for a revised molecular dogma in which the noncoding genome is recognized as a major regulator of cellular function, oncogenic transformation, and immune surveillance.
Maria Lteif, Assia Hijazi, E. Morgand et al.· Oncoimmunology· 0 citations
This review will focus on the newly identified functions of non-coding RNAs (ncRNAs) in cancer biology and therapeutic innovations, and reviews the existing knowledge on microRNAs, long non-coding RNAs, and circular RNAs in the context of their different experimental and computational studies.
Li Qiu, Zenan Xu, Jianxiong Xu et al.· Biomolecules· 0 citations
This review examines how different types of ncRNAs contribute to cancer initiation, progression, and treatment resistance, and assesses their potential as diagnostic markers, prognostic factors, and therapeutic targets.
Akanksha Samuel, G. Calin· Carcinogenesis· 0 citations
Cells in multicellular eukaryotic systems are diverse biological units, with characteristics and functions determined by their molecular profiles. CRISPR–Cas9 genome editing has been widely used across biology to modulate gene expression and study gene function. However, there is currently no versatile and scalable method for editing a cell’s genome in response to endogenous cellular signals. Here, we report the engineering of a CRISPR guide RNA that efficiently confers genome editing in response to the catalytic activity of a target microRNA (miRNA) within a cell. miRNAs are short non-coding RNAs that are widely conserved across eukaryotes and can cleave their target RNA through almost perfect base pairing. In mammals, miRNAs are largely involved in development and homeostasis as well as disease progression and developmental disorders. To leverage these properties for genome editing, we developed a cuffed guide RNA (cgRNA) which is composed of a permutated order of sequence domains from the commonly used single guide RNA (sgRNA). These permutated domains were then concatenated with a miRNA target sequence, yielding a warped guide RNA that is inactive until cleaved by a complementary miRNA. We demonstrated that cgRNA enabled efficient miRNA activity-dependent genome editing in human and mouse cell lines. Biochemical and structural analyses revealed three stages of inhibition of the CRISPR genome-editing pathway for unprocessed cgRNA. Utilizing a lentiviral library of cgRNAs containing miRNA targets covering mouse genome-wide miRNAs, we identified miRNA cleavage activities and their sequence specificities in mouse embryonic stem cells and during smooth muscle cell differentiation. Furthermore, we showed that endogenous mRNA expression could be irreversibly recorded into a DNA sequence using a cgRNA targeted by a synthetic miRNA repeat. cgRNA is a simple, robust, miRNA activity-gated genome editing system that could facilitate the development of cell state-specific genome editing, the mapping of miRNA activity and gene expression landscapes, and the recording of molecularly determined cell states during the long-term progression of multicellular systems.
Arman Adel, Yuta Shuto, Shunsuke Kawasaki et al.· bioRxiv· 0 citations
It is proposed that the upregulated lncRNA ENSG00000265613 may enhance malignancy by stabilizing the RNA target ENSG00000582008 in luminal A breast cancer, particularly given its established role in oncogenesis.
C. Guda, Sankarasubramanian Jagadesan, Avinash M. Veerappa· Methods in molecular biology· 0 citations
This review integrates the molecular logic of splice-site selection with the cancer-specific mechanisms that perturb it, summarizes representative isoform switches across the hallmarks of cancer, evaluates emerging technologies and clinical biomarkers, and discusses the opportunities and constraints of translating splicing biology into precision oncology.